Quick Answer
ArriVent BioPharma, Inc. reported Net Income of -$166.31 million for fiscal year 2025.
ArriVent BioPharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$166.31M -106.6% |
-$80.49M -16.1% |
-$69.33M | — |
| Diluted EPS | -$4.32 -68.8% |
-$2.56 +92.1% |
-$32.38 | — |
| Total Assets | $333.17M +21.2% |
$274.94M +68.6% |
$163.10M | — |
| Cash and Equivalents | $45.54M -38.7% |
$74.29M -50.6% |
$150.39M | — |
| Stockholders Equity | $307.22M +19.2% |
$257.65M +268.2% |
-$153.19M -80.0% |
-$85.11M |
| R&D Expense | $153.35M +94.1% |
$79.00M +21.8% |
$64.88M | — |
| Operating Income | -$177.53M -88.2% |
-$94.31M -26.4% |
-$74.59M | — |
| Shares Outstanding | 42.45M +25.9% |
33.71M +1127.7% |
2.75M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$34.98M | -70.1% | -11.4% |
| Diluted EPS | September 30, 2025 | -$0.83 | -36.1% | +7.8% |
| Total Assets | September 30, 2025 | $326.56M | +11.6% | +21.2% |
| Cash and Equivalents | September 30, 2025 | $112.67M | -60.2% | -0.1% |
| Stockholders Equity | September 30, 2025 | $305.00M | +9.9% | +22.1% |
| R&D Expense | September 30, 2025 | $32.17M | +60.1% | +16.0% |
| Operating Income | September 30, 2025 | -$38.32M | -58.1% | -14.0% |
| Shares Outstanding | September 30, 2025 | 40.85M | +21.2% | +9.0% |
- ArriVent BioPharma, Inc. reported Net Income of -$166.31 million for fiscal year 2025.
- ArriVent BioPharma, Inc. showed a decrease of -106.6% in Net Income compared to the prior fiscal year.
- ArriVent BioPharma, Inc. reported Diluted EPS of $4.32 per share (loss) for fiscal year 2025.
- ArriVent BioPharma, Inc. showed a decrease of -68.8% in Diluted EPS compared to the prior fiscal year.
- ArriVent BioPharma, Inc. reported Total Assets of $333.17 million for fiscal year 2025.
- ArriVent BioPharma, Inc. showed an increase of +21.2% in Total Assets compared to the prior fiscal year.
- ArriVent BioPharma, Inc. reported Cash and Equivalents of $45.54 million for fiscal year 2025.
- ArriVent BioPharma, Inc. showed a decrease of -38.7% in Cash and Equivalents compared to the prior fiscal year.
- ArriVent BioPharma, Inc. reported Stockholders Equity of $307.22 million for fiscal year 2025.
- ArriVent BioPharma, Inc. showed an increase of +19.2% in Stockholders Equity compared to the prior fiscal year.
- ArriVent BioPharma, Inc. reported R&D Expense of $153.35 million for fiscal year 2025.
- ArriVent BioPharma, Inc. showed an increase of +94.1% in R&D Expense compared to the prior fiscal year.
- ArriVent BioPharma, Inc. reported Operating Income of -$177.53 million for fiscal year 2025.
- ArriVent BioPharma, Inc. showed a decrease of -88.2% in Operating Income compared to the prior fiscal year.
- ArriVent BioPharma, Inc. reported Shares Outstanding of 42.45 million shares for fiscal year 2025.
- ArriVent BioPharma, Inc. showed an increase of +25.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: